BTK and B-cell chronic lymphocytic leukemia: Aberrations in BIRC3are associated with worse outcomes in CLL patients and resistance to ibrutinib, a covalent inhibitor of Bruton’s tyrosine kinase (BTK) (Jiang et al. 2016).